Q2 Holdings Aktie
WKN DE: A1XEYE / ISIN: US74736L1098
06.08.2025 23:32:48
|
Immunome (IMNM) Q2 Revenue Surges 382%
Immunome (NASDAQ:IMNM), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantial revenue beat, with $4.0 million in GAAP revenue topping analyst forecasts by a wide margin, plus a narrower-than-expected GAAP loss per share. GAAP revenue was well ahead of consensus. Overall, the period reflected significant cash investment and pipeline activity, but also highlighted the absence of commercial-stage products. Source: Analyst estimates for the quarter provided by FactSet. Immunome is focused on discovering and developing new targeted cancer treatments. The approach combines antibody-drug conjugates (ADCs)—targeted cancer drugs that deliver chemotherapy directly to cancer cells—and other modalities. The pipeline includes several investigational medicines, such as varegacestat for desmoid tumors, IM-1021 for solid tumors and blood cancers, and preclinical ADC candidates for various cancer types.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Q2 Holdings Incmehr Nachrichten
29.07.25 |
Ausblick: Q2 veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
06.05.25 |
Ausblick: Q2 legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu Q2 Holdings Incmehr Analysen
Aktien in diesem Artikel
Immunome Inc Registered Shs | 12,38 | 7,93% |
|
Q2 Holdings Inc | 57,00 | 0,88% |
|